Recursion Pharmaceuticals (RXRX) Competitors

Elanco Animal Health (NYSE:ELAN) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.

Which has higher valuation and earnings, ELAN or RXRX?

Recursion Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.43B	1.47	-$1.23B	$0.74	17.68
Recursion Pharmaceuticals	$59.82M	30.92	-$328.07M	-$1.77	-2.57

Does the media prefer ELAN or RXRX?

In the previous week, Elanco Animal Health had 11 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 19 mentions for Elanco Animal Health and 8 mentions for Recursion Pharmaceuticals. Elanco Animal Health's average media sentiment score of 1.34 beat Recursion Pharmaceuticals' score of 1.24 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	14 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in ELAN or RXRX?

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 0.9% of Elanco Animal Health shares are held by company insiders. Comparatively, 15.8% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate ELAN or RXRX?

Elanco Animal Health presently has a consensus price target of $15.17, suggesting a potential upside of 15.95%. Recursion Pharmaceuticals has a consensus price target of $7.60, suggesting a potential upside of 67.03%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community prefer ELAN or RXRX?

Elanco Animal Health received 112 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. However, 56.14% of users gave Recursion Pharmaceuticals an outperform vote while only 54.96% of users gave Elanco Animal Health an outperform vote.

Company	Underperform	Outperform
Elanco Animal Health	Outperform Votes 144 54.96%	Underperform Votes 118 45.04%
Recursion Pharmaceuticals	Outperform Votes 32 56.14%	Underperform Votes 25 43.86%

Which has more volatility and risk, ELAN or RXRX?

Elanco Animal Health has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.

Is ELAN or RXRX more profitable?

Elanco Animal Health has a net margin of 4.60% compared to Recursion Pharmaceuticals' net margin of -579.52%. Elanco Animal Health's return on equity of 6.78% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	4.60%	6.78%	3.03%
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%

Summary

Elanco Animal Health beats Recursion Pharmaceuticals on 13 of the 18 factors compared between the two stocks.